YOUR CONDITION, EXPLAINED
Malignant Neoplasms of the Endocrine System (Including Thyroid Cancer) VA disability rating & claim guide
The VA rates Malignant Neoplasms of the Endocrine System (Including Thyroid Cancer) under diagnostic code 7914, in 38 CFR § 4.119 (endocrine system), and the schedule provides a single evaluation under it: 100%.
Free · No account needed
Save your Malignant Neoplasms of the Endocrine System (Including Thyroid Cancer) guide
Email yourself this Malignant Neoplasms of the Endocrine System (Including Thyroid Cancer) guide so the rating criteria, evidence checklist, and preparation tips are easy to find later.
A CLEARER PATH FORWARD
Make sense of your next step.
01Understand the rating02Know what to gather03Plan your preparationTHE ESSENTIALS
How the VA rates Malignant Neoplasms of the Endocrine System (Including Thyroid Cancer)
DC 7914 covers a malignant — cancerous — neoplasm in any specified part of the endocrine system, thyroid cancer included. It carries one evaluation, 100 percent, and no lower tier of its own. That 100 percent continues through treatment and beyond it; six months after treatment is discontinued, a mandatory VA examination determines the rating that follows, and where there has been no local recurrence or metastasis the evaluation is then based on the residuals.
DC 7914 states a single criterion — "Neoplasm, malignant, any specified part of the endocrine system" — evaluated at 100 percent. Its Note controls everything after that: "A rating of 100 percent shall continue beyond the cessation of any surgical, X-ray, antineoplastic chemotherapy or other therapeutic procedure. Six months after discontinuance of such treatment, the appropriate disability rating shall be determined by mandatory VA examination. Any change in evaluation based upon that or any subsequent examination shall be subject to the provisions of § 3.105(e) of this chapter. If there has been no local recurrence or metastasis, rate on residuals." Two things follow from that. The 100 percent evaluation is not graded by symptom severity — it attaches to the malignancy and to the treatment period, and the six months runs from the date treatment was discontinued. And there is no lower percentage under DC 7914 itself: once the mandatory examination has been done and there is no local recurrence or metastasis, the evaluation comes from the residuals, each rated under whichever diagnostic code fits it. A change of evaluation based on that examination or any later one is subject to § 3.105(e).
- Diagnostic code
- 7914
- Rating schedule
- 38 CFR § 4.119
- Schedule levels
- 100%
How does the VA choose a rating level?
There is no higher or lower step inside this code: a rating decision either finds its criteria met or it does not. Where they are not met, 38 CFR § 4.31 assigns a 0% evaluation: service connection granted, at a level that does not pay.
EXPLORE THE PERCENTAGES
Malignant Neoplasms of the Endocrine System (Including Thyroid Cancer) VA rating criteria (DC 7914)
This condition has one published rating level. Read the criteria, then explore the details and monthly pay.
These are published rating criteria. Selecting a level does not predict your VA decision.
IN THE REGULATION’S OWN WORDS
What 38 CFR also says about Malignant Neoplasms of the Endocrine System (Including Thyroid Cancer)
The notes 38 CFR Part 4 prints with these criteria, quoted. They govern how the evaluation is made without being a rating level themselves.
- “Note: A rating of 100 percent shall continue beyond the cessation of any surgical, X-ray, antineoplastic chemotherapy or other therapeutic procedure. Six months after discontinuance of such treatment, the appropriate disability rating shall be determined by mandatory VA examination. Any change in evaluation based upon that or any subsequent examination shall be subject to the provisions of § 3.105(e) of this chapter. If there has been no local recurrence or metastasis, rate on residuals.”DC 7914
BUILD YOUR EVIDENCE, ONE PIECE AT A TIME
Evidence for your Malignant Neoplasms of the Endocrine System (Including Thyroid Cancer) claim
A long list feels easier when you have a place to start. Use this checklist to see what you have and what still needs gathering.
Check off what you’ve gathered. Progress stays on this page until you leave or refresh.
THE EXAM FORM
Which DBQ is used for Malignant Neoplasms of the Endocrine System (Including Thyroid Cancer)?
VA publishes its questionnaires by body system; find the one for this condition on VA's list.
Source: VA: Public Disability Benefits Questionnaires (DBQs), read September 18, 2026.
SMALL DETAILS. BETTER PREPARATION.
Preparing your Malignant Neoplasms of the Endocrine System (Including Thyroid Cancer) claim
Start with the practical tips, then explore the common oversights. You don’t need to work through everything at once.
Practical tips for your claim4 tips
- 01
Pin down the date the last therapeutic procedure was discontinued. The Note runs its six-month period from that date, and that is what fixes when the mandatory VA examination is due.
- 02
Keep the complete treatment record — surgery, X-ray therapy, antineoplastic chemotherapy, or other therapeutic procedures — since the Note ties the duration of the 100 percent evaluation to those procedures and their cessation.
- 03
Have the residuals documented before the mandatory examination rather than after it. Where there is no local recurrence or metastasis, the Note directs the rating to the residuals, and each is evaluated under the diagnostic code that covers it.
- 04
A change of evaluation following that examination, or any subsequent one, is subject to § 3.105(e) — the procedure the Note itself names.
C&P exam pitfalls to keep in mind3 tips
- 01
A mandatory examination that goes forward with no record of what the residuals actually are, leaving the evaluation that follows the 100 percent period resting on very little.
- 02
Treatment records that never state the date therapy was discontinued, which is the date the Note's six-month period runs from.
- 03
An examination that addresses only the affected gland and not the other residuals of surgery, radiation, or chemotherapy, which the Note directs the rating to.
Common filing mistakes4 tips
- 01
Filing the diagnosis without the treatment record. The Note ties the duration of the 100 percent evaluation to the therapeutic procedures and their cessation.
- 02
Treating the end of the 100 percent period as the end of the claim. Under the Note the evaluation continues on residuals, each under the diagnostic code that covers it.
- 03
No follow-up imaging or oncology note addressing recurrence or metastasis, which the Note makes the pivot at the mandatory examination.
- 04
Filing a thyroid-function claim here. An overactive thyroid is DC 7900, "Hyperthyroidism, including, but not limited to, Graves' disease"; DC 7914 is the malignant-neoplasm code.
When symptoms may first appear2 tips
- 01
DC 7914's timeline is set by treatment rather than by symptoms: the 100 percent evaluation continues beyond the cessation of any surgical, X-ray, antineoplastic chemotherapy, or other therapeutic procedure, and the six-month period before the mandatory VA examination starts when that treatment is discontinued.
- 02
After that examination, and absent local recurrence or metastasis, what remains to be evaluated is the residuals — which is why records of what the treatment left behind matter from the start.
THE BROADER PICTURE
Malignant Neoplasms of the Endocrine System (Including Thyroid Cancer) by the numbers
- Veterans service-connected
- ~2,700 veterans
Vetrify editorial estimates informed by VA published claims data (VBA Annual Benefits Report) and the VA rating schedule, not official VA statistics.
LET’S CLEAR A FEW THINGS UP
Common questions about Malignant Neoplasms of the Endocrine System (Including Thyroid Cancer)
Is Malignant Neoplasms of the Endocrine System (Including Thyroid Cancer) a VA-rated disability?
Yes. The VA rates Malignant Neoplasms of the Endocrine System (Including Thyroid Cancer) under VASRD diagnostic code 7914 (Endocrine System). DC 7914 covers a malignant — cancerous — neoplasm in any specified part of the endocrine system, thyroid cancer included. It carries one evaluation, 100 percent, and no lower tier of its own. That 100 percent continues through treatment and beyond it; six months after treatment is discontinued, a mandatory VA examination determines the rating that follows, and where there has been no local recurrence or metastasis the evaluation is then based on the residuals.
What VA disability rating can I get for Malignant Neoplasms of the Endocrine System (Including Thyroid Cancer)?
Possible VA ratings for Malignant Neoplasms of the Endocrine System (Including Thyroid Cancer) are 100%, 0%. The 0% level comes from 38 CFR 4.31, which assigns it wherever no compensable level is met. Examples: 100%: "Neoplasm, malignant, any specified part of the endocrine system." DC 7914 states this one evaluation and no lower tier. Its Note controls how long the evaluation runs: "A rating of 100 percent shall continue beyond the cessation of any surgical, X-ray, antineoplastic chemotherapy or other therapeutic procedure. Six months after discontinuance of such treatment, the appropriate disability rating shall be determined by mandatory VA examination. Any change in evaluation based upon that or any subsequent examination shall be subject to the provisions of § 3.105(e) of this chapter. If there has been no local recurrence or metastasis, rate on residuals." So there is no lower percentage under DC 7914 itself — after the mandatory examination the evaluation comes from the residuals, each rated under whichever diagnostic code fits it.
What evidence helps prove Malignant Neoplasms of the Endocrine System (Including Thyroid Cancer) for VA disability?
Strong evidence for a Malignant Neoplasms of the Endocrine System (Including Thyroid Cancer) claim includes: The pathology report establishing the malignancy and the part of the endocrine system involved; Oncology and surgical records showing each therapeutic procedure and the date the last one was discontinued, which is when the Note's six-month period begins; Post-treatment imaging and follow-up notes addressing local recurrence and metastasis, the finding the Note makes decisive at the mandatory examination; Documentation of the residuals of treatment, since these carry the evaluation once the 100 percent period ends.
What mistakes should veterans avoid when claiming Malignant Neoplasms of the Endocrine System (Including Thyroid Cancer)?
Common pitfalls when filing for Malignant Neoplasms of the Endocrine System (Including Thyroid Cancer): Filing the diagnosis without the treatment record. The Note ties the duration of the 100 percent evaluation to the therapeutic procedures and their cessation; Treating the end of the 100 percent period as the end of the claim. Under the Note the evaluation continues on residuals, each under the diagnostic code that covers it; No follow-up imaging or oncology note addressing recurrence or metastasis, which the Note makes the pivot at the mandatory examination; Filing a thyroid-function claim here. An overactive thyroid is DC 7900, "Hyperthyroidism, including, but not limited to, Graves' disease"; DC 7914 is the malignant-neoplasm code.
Official sources
- 38 CFR § 4.119, Schedule of ratings, endocrine system (Diagnostic Code 7914)
- 38 CFR § 4.31, zero percent evaluations
Criteria in quotation marks are the regulation’s own words; everything else on this page is Vetrify’s summary of it. The eCFR text is authoritative. See how Vetrify derives its numbers.
How these figures are checked: our methodology and the open dataset.
VA Calc: Disability Pay
Combine your ratings & see monthly pay on your iPhone · Works offline